Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Recursion Pharmaceuticals (RXRX)
NASDAQ:RXRX
RESEARCH TOOLSreports
Recursion Pharmaceuticals (RXRX) Stock Price & Analysis
1,412 Followers
RXRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.97 - $16.75
Previous Close$7.46
Volume6.26M
Average Volume (3M)5.37M
Market Cap
$2.00B
Enterprise Value$1.66B
Total Cash (Recent Filing)$391.56M
Total Debt (Recent Filing)$50.67M
Price to Earnings (P/E)―
Beta2.86
Next Earnings
Aug 06, 2024EPS Estimate
-$0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.60
Shares Outstanding237,663,668
10 Day Avg. Volume4,261,192
30 Day Avg. Volume5,369,429
Standard Deviation0.30
R-Squared0.02
Alpha-0.00679
Financial Highlights & Ratios
Price to Book (P/B)5.61
Price to Sales (P/S)46.45
Price to Cash Flow (P/CF)-7.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue37.50
Enterprise Value/Gross Profit835.82
Enterprise Value/Ebitda-11.68
Forecast
1Y Price Target
$15.67Price Target Upside118.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Recursion Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Collaborations And PartnershipsBayer's participation as the first beta user of Recursion's software underscores confidence from a major pharmaceutical company.
Investment And ConfidenceNVIDIA's $50 million investment in RXRX signifies strong confidence in the company's platform potential.
Technological AdvancementsRecursionOS is expanding rapidly with new supercomputing capabilities, enhancing drug discovery efficiency.
Bears Say
AI Drug DiscoverySkepticism around AI drug discovery remains, particularly regarding accessibility of metadata, data management, and integration of multi-discipline information.
Clinical DataThe current lack of clinical proof-of-concept represents a key component of the bear thesis among biotech investors.
R&D SpendingR&D of $67.6mm was below consensus of $73.8mm.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
RXRX FAQ
What was Recursion Pharmaceuticals’s price range in the past 12 months?
Recursion Pharmaceuticals lowest stock price was $4.97 and its highest was $16.75 in the past 12 months.
What is Recursion Pharmaceuticals’s market cap?
Currently, no data Available
When is Recursion Pharmaceuticals’s upcoming earnings report date?
Recursion Pharmaceuticals’s upcoming earnings report date is Aug 06, 2024 which is in 34 days.
How were Recursion Pharmaceuticals’s earnings last quarter?
Recursion Pharmaceuticals released its earnings results on May 09, 2024. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.423 by $0.033.
Is Recursion Pharmaceuticals overvalued?
According to Wall Street analysts Recursion Pharmaceuticals’s price is currently Undervalued.
Does Recursion Pharmaceuticals pay dividends?
Recursion Pharmaceuticals does not currently pay dividends.
What is Recursion Pharmaceuticals’s EPS estimate?
Recursion Pharmaceuticals’s EPS estimate is -$0.4.
How many shares outstanding does Recursion Pharmaceuticals have?
Recursion Pharmaceuticals has 261,043,030 shares outstanding.
What happened to Recursion Pharmaceuticals’s price movement after its last earnings report?
Recursion Pharmaceuticals reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.423. Following the earnings report the stock price went down -0.463%.
Which hedge fund is a major shareholder of Recursion Pharmaceuticals?
Among the largest hedge funds holding Recursion Pharmaceuticals’s share is ARK Investment Management LLC. It holds Recursion Pharmaceuticals’s shares valued at 245M.
---
Recursion Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.67 (118.85% Upside)
$15.67 (118.85% Upside)
Blogger Sentiment
Bullish
RXRX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.13%
12-Months-Change
Fundamentals
Return on Equity
-85.19%
Trailing 12-Months
Asset Growth
-11.08%
Trailing 12-Months
Company Description
Recursion Pharmaceuticals
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
---
RXRX Earnings Call
Q1 2024
0:00 / 0:00
---
RXRX Stock 12 Month Forecast
Average Price Target
$15.67
▲(118.85% Upside)
Technical Analysis
Best Analysts Covering RXRX
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
+2.81%
reiterated a buy rating 10 months ago
Copying Gaurav Goparaju's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +2.81% per trade.
---